Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma

BACKGROUND: Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited. METHODS: In this study, human osteosarcoma cell lines were prepar...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yitian, Yu, Wei, Zhu, Jian, Wang, Junjie, Xia, Kaishun, Liang, Chengzhen, Tao, Huimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471997/
https://www.ncbi.nlm.nih.gov/pubmed/30995926
http://dx.doi.org/10.1186/s13046-019-1147-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471997/
https://www.ncbi.nlm.nih.gov/pubmed/30995926
http://dx.doi.org/10.1186/s13046-019-1147-6

Ejemplares similares